Clinical Trials · NCT04466904
Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM
- Phase
- Phase 1/Phase 2
- Recruitment status
- Completed
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Enrollment
- 42
- Start date
- Sep 2020
- Locations
- 1 site, China
- Primary endpoint
- To assess the number and incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of IBI362 compared with placebo